Johns Hopkins Drug Access and Affordability Initiative
The blueprint seeks to increase competition and improve the negotiation of drug prices, reduce consumers' out-of-pocket spending on medicines, and create incentives to lower list prices. Learn More
An antitrust lawsuit against Sacramento, Calif.-based Sutter Health over prices could have a national effect, according to a Kaiser Health News report published by the LA Times. LEARN MORE
Gerard Anderson, Professor of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health, speaks about prescription drug costs and President Trump's plan to lower them. LEARN MORE
The Johns Hopkins Drug Access and Affordability Initiative focuses on developing bipartisan policy recommendations to address the costs of pharmaceuticals in the United States.
Our proposals attempt to balance the need for innovation, the need to improve patients’ access to medications, and the need to reduce overall medical costs to federal and state governments and other payers in our health care system.
The Latest at JHDAAI
Pharmaceuticals: The Challenge of Balancing Innovation with Access
This report from the Johns Hopkins Drug Access and Affordability Initiative provides an introduction to trends and reasons for rising drug prices in the United States.Learn More